CAR-T Therapy: Multiple Myeloma Cure Potential
- A recent study published in the journal of Clinical Oncology indicates that ciltacabtagene autoleucel (cilta-cel), a form of CAR-T cell therapy, can provide long-lasting remission for patients with...
- Multiple myeloma, a blood cancer, often becomes resistant to treatments after initial success, especially in patients who have undergone multiple therapies.
- The CARTITUDE-1 trial evaluated cilta-cel, a chimeric antigen receptor (CAR) T-cell therapy.
CAR-T cell therapy shows exciting promise for multiple myeloma patients, offering the potential for long-lasting remission.The latest research,published in the Journal of Clinical Oncology,highlights how ciltacabtagene autoleucel (cilta-cel) is substantially improving outcomes for those with relapsed or refractory multiple myeloma (RRMM),a blood cancer frequently enough resistant to previous treatments. This study, with a five-year follow-up, reveals that a substantial portion of patients remain alive and progression-free after a single cilta-cel infusion. Furthermore, the research identifies key factors, such as lower tumor burden and higher T-cell counts, which correlate with sustained remission. The safety profile remains consistent with previous findings, providing a beacon of hope. News Directory 3 is here to share the latest developments, offering insights into the ongoing clinical trials. Discover what’s next regarding this groundbreaking therapy soon.
CAR-T Cell Therapy Shows Promise in Multiple Myeloma Treatment
A recent study published in the journal of Clinical Oncology indicates that ciltacabtagene autoleucel (cilta-cel), a form of CAR-T cell therapy, can provide long-lasting remission for patients with relapsed or refractory multiple myeloma (RRMM).
Multiple myeloma, a blood cancer, often becomes resistant to treatments after initial success, especially in patients who have undergone multiple therapies. Ancient data show that patients with RRMM typically have a median progression-free survival of less than six months and an overall survival of about one year.
The CARTITUDE-1 trial evaluated cilta-cel, a chimeric antigen receptor (CAR) T-cell therapy. Researchers conducted a post hoc analysis to assess overall survival, sustained remission, immunologic biomarkers, and safety after a single cilta-cel infusion.
The study involved 97 patients with RRMM who had previously received at least three lines of therapy. Nearly all were triple-class refractory. these patients received a single cilta-cel infusion between July 2018 and October 2019 across various clinical sites.
Over a median follow-up of 61.3 months, survival and progression were monitored using Kaplan-Meier methods. Thirty-two patients (33%) remained alive and progression-free five years post-infusion, without maintenance therapy. Thirty-one of these 32 patients achieved stringent complete remission, as resolute by independent review.
Furthermore, 12 patients at a single center underwent serial evaluations and tested negative for minimal residual disease and imaging at year five or later.
The study found that patients who remained progression-free tended to have lower tumor burden, higher hemoglobin and platelet counts at baseline, and a greater proportion of naive T cells in the infused product. They also exhibited higher effector-to-target ratios, greater peak expansion of CAR-positive T cells, and more favorable T cell-to-neutrophil ratios.
The safety profile of cilta-cel remained consistent with prior reports, with no new cases of parkinsonism or cranial nerve palsies. Among long-term responders, there were reports of two second primary malignancies, two neurologic events, and four grade 3 or higher infections.
Investigators consider these findings the longest reported follow-up for CAR-T therapy in multiple myeloma to date. They suggest that cilta-cel may offer perhaps curative outcomes for a subset of patients with multiple myeloma.
Clinical trials are ongoing to evaluate cilta-cel in earlier lines of therapy, aiming to extend long-term, treatment-free survival to a broader range of patients with this blood cancer.